Drug company Apotex is recalling two lots of APO-Mometasone nasal spray due to possible bacterial contamination. A sign is displayed in front of Health Canada headquarters in Ottawa on Friday, January 3, 2014. THE CANADIAN PRESS/Sean Kilpatrick
Apotex, a pharmaceutical company, is issuing a recall for two lots of a prescription nasal spray due to potential bacterial contamination concerns.
The nasal spray in question, APO-Mometasone, is typically prescribed to address allergy symptoms in children, sinusitis in patients aged 12 and older, and nasal polyps in adults.
According to Health Canada, the recalled lots may contain Burkholderia cepacia complex bacteria, which could pose significant health risks, particularly to individuals with chronic lung diseases, weakened immune systems, pregnant women, seniors, and children.
The affected APO-Mometasone sprays are identified by lot numbers TX5343 and TZ2586, with expiry dates set for September and October 2025.
Health Canada advises individuals who possess the recalled sprays to return them to their local pharmacy for appropriate disposal. Those who have used the product and are concerned about potential health implications are encouraged to consult a healthcare professional.
While Burkholderia cepacia complex bacteria present a low risk to most healthy individuals, symptoms of infection may include fever and facial pain or pressure.
